Employment of the Envisia Genomic Classifier in Conjunction with Cryobiopsy in Patient with Undiagnosed Interstitial Lung Disease

Retrospective analysis of patients in a multi-center study assessing change in management strategy following Envisia and cryobiopsy and the association between Envisia UIP classification and disease progression. Results showed combining Envisia with Cryobiopsy demonstrated meaningful impact on therapeutic strategy for ILD patients. Envisia positive patients who were not prescribed antifibrotics were twice as likely to progress compared to Envisia negative patients.